| miRs-17-3P and 5p, miR-18a-5p, miR-18b-5P, miR-19a-3p, miR-19b-3p and 92a-3p |
Down |
OncomiRNAs; belongs to the miR-17-92 cluster; positively regulated by c-MYC and overexpressed in MM. members of the miR-17-92 cluster target SOCS1 and BIM. |
[46, 47, 49] |
| Let-7c-5p, Let-7f-5p, Let-7g-5p and Let-7i-5p |
Down |
Members of the Let-7 oncomiRNA family; overexpressed in MM; promote angiogenesis |
[49] |
| miR-106b and miR-25-3p |
Down |
OncomiRNA; belongs to the miR-106b-25 cluster; overexpressed in MM; controls P53 activity |
[46, 48, 49] |
| miRs-125b |
Down |
OncomiRNA, targets P53. |
[51] |
| miR-20a-5p and miR-148a |
Down |
Over expressed in MM compared with normal PCs with a prognostic value |
[66] |
| miR-125a-3p, miR-198 |
Up |
Downregulated in MM cell lines and patient samples; upregulated in MM cell lines upon treatment with 5´-aza |
[46, 54–56] |
| miR-601, miR-765, miR-877-5p |
Up |
DNA hypermethylated in MM patients samples, upregulated in MM cell lines upon treatment with 5-aza-CdR |
[44] |
| miR-1290, miR-223-3p, miR-320c, miR-630 |
Up |
Upregulated in MM cell lines upon treatment with 5-aza-CdR |
[44] |
